Jeffes E W, Lee G C, Said S, Sabahi M, McCullough J L, Herrod R, Alzona C P, Linden K G, Soundararajan D, Edwards S
Department of Dermatology, V.A. Medical Center, Long Beach 90822, USA.
J Invest Dermatol. 1995 Dec;105(6):733-8. doi: 10.1111/1523-1747.ep12325496.
Although psoriasis is characterized by the accumulation of activated proliferating lymphoid cells in the psoriatic skin lesion, it is not known whether these cells are activated and proliferating before entry into the psoriatic plaque. The current study evaluates the number and phenotype of proliferating lymphoid cells in the blood of psoriatic patients. Proliferation of peripheral blood mononuclear cells was evaluated on cytospun preparations of these cells using autoradiographic techniques after pulsing the mononuclear cells with 3H-methyl thymidine for 2 h. The phenotypes of the labeled peripheral blood mononuclear cells were determined combining autoradiography and immunohistochemistry with monoclonal antibodies directed at CD3, CD4, CD8, CD11c, CD22, and human leukocyte antigen-DR. The data demonstrated elevated numbers of proliferating lymphoid cells in the blood of psoriatic patients compared with normal nonpsoriatic volunteers (p < 0.01). Furthermore, the number of circulating proliferating mononuclear cells increased significantly with increasing psoriasis skin disease severity (correlation coefficient 0.95; p < 0.0001). When the phenotype of the proliferating cells in the blood was examined, the numbers of T cells (CD3+, CD4+, CD8+ cells), B cells (CD22+ cells), monocytes (CD11c+ cells), and human leukocyte antigen-DR+ cells were significantly elevated compared with nonpsoriatic skin (p < 0.01) and increased with increasing disease activity (correlation coefficient range 0.48-0.74; p < 0.05). The data suggest a generalized systemic activation of T, B, and monocytic cells that results in labeling of up to 0.16% of the circulating mononuclear cells with 3H-methyl thymidine (i.e., proliferating and presumably activated) when assayed in vitro.
虽然银屑病的特征是在银屑病皮损中存在活化增殖的淋巴细胞积聚，但尚不清楚这些细胞在进入银屑病斑块之前是否已被激活并增殖。当前研究评估了银屑病患者血液中增殖淋巴细胞的数量和表型。在用³H-甲基胸腺嘧啶核苷脉冲单核细胞2小时后，使用放射自显影技术在这些细胞的细胞涂片制备物上评估外周血单核细胞的增殖情况。结合放射自显影和免疫组织化学，使用针对CD3、CD4、CD8、CD11c、CD22和人类白细胞抗原-DR的单克隆抗体来确定标记的外周血单核细胞的表型。数据表明，与正常非银屑病志愿者相比，银屑病患者血液中增殖淋巴细胞的数量有所增加（p < 0.01）。此外，循环增殖单核细胞的数量随着银屑病皮肤病严重程度的增加而显著增加（相关系数0.95；p < 0.0001）。当检查血液中增殖细胞的表型时，与非银屑病皮肤相比，T细胞（CD3⁺、CD4⁺、CD8⁺细胞）、B细胞（CD22⁺细胞）、单核细胞（CD11c⁺细胞）和人类白细胞抗原-DR⁺细胞的数量显著升高（p < 0.01），并且随着疾病活动度的增加而增加（相关系数范围为0.48 - 0.74；p < 0.05）。数据表明T、B和单核细胞存在全身性的系统激活，在体外检测时，这导致高达0.16%的循环单核细胞被³H-甲基胸腺嘧啶核苷标记（即增殖且可能被激活）。
